Executive Wealth Management LLC Has $8.19 Million Stake in Johnson & Johnson (NYSE:JNJ)

Executive Wealth Management LLC increased its position in Johnson & Johnson (NYSE:JNJ) by 0.1% in the fourth quarter, HoldingsChannel reports. The firm owned 52,227 shares of the company’s stock after acquiring an additional 74 shares during the period. Executive Wealth Management LLC’s holdings in Johnson & Johnson were worth $8,186,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of JNJ. DORCHESTER WEALTH MANAGEMENT Co raised its holdings in shares of Johnson & Johnson by 8.6% during the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after purchasing an additional 5,327 shares in the last quarter. Cantor Fitzgerald Investment Advisor L.P grew its position in Johnson & Johnson by 88.9% in the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock worth $31,049,000 after purchasing an additional 82,429 shares during the last quarter. AMI Investment Management Inc. increased its stake in Johnson & Johnson by 8.8% in the first quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after acquiring an additional 1,475 shares during the period. Equitable Holdings Inc. increased its stake in Johnson & Johnson by 4.9% in the first quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after acquiring an additional 2,119 shares during the period. Finally, USS Investment Management Ltd increased its stake in Johnson & Johnson by 2.4% in the first quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after acquiring an additional 20,528 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.0 %

Shares of NYSE JNJ opened at $147.49 on Tuesday. The company’s 50 day simple moving average is $157.07 and its 200 day simple moving average is $155.90. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $175.97. The firm has a market capitalization of $355.42 billion, a P/E ratio of 10.68, a P/E/G ratio of 2.48 and a beta of 0.53. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.16 and a quick ratio of 0.91.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, beating the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a net margin of 37.79% and a return on equity of 37.27%. The business had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same period in the prior year, the business posted $2.35 earnings per share. Johnson & Johnson’s revenue was down 9.7% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post 10.66 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 24th. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research note on Monday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 28th. Finally, Raymond James upped their price objective on shares of Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 3rd. Seven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $177.31.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the stock in a transaction on Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the sale, the executive vice president now directly owns 141,416 shares in the company, valued at $22,099,078.32. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the stock in a transaction on Friday, February 16th. The stock was sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the sale, the insider now owns 4,099,575 shares in the company, valued at $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.